Major Milestone | Biotroy Therapeutics, in collaboration with Fudan University, has secured Japanese patent approval for its CD3L1 target, Bolstering Global IP Layout.
2026-09-22
BioTroy Therapeutics Jointly Approved for Key Research Project
2024-12-27
Cell: BioTroy discovered the first ligand of CD3 as target for cancer immunotherapy
2024-04-12
BioTroy was awarded the"2023 Top 15 Chinese Innovative and Emerging Pharmaceutical Enterprise"
2024-03-29
BioTroy obtained two important qualifications
2024-03-01
Cell Reports Medicine: BioTroy Therapeutics jointly published Galectin-8’s role in tumor immune evasion
2024-01-26
